BMET - Biomet $38.44 (+1.63)

There probably is not an orthopedic surgeon alive who has not heard of Biomet. The Company is a worldwide leader in developing and marketing a myriad of tools and equipment that have changed orthopedic surgical procedures as well as rehabilitative treatments. The Company even has a presence in dentistry because they also make reconstructive dental implants. (NHL players are probably very familiar with the Company as well). Through the first 3 quarters this year, profits grew by 18%. When Biomet reports earnings on December 13th, it should cap off a very good year. Analysts expect profits of $0.29 a share. At first glance, it may appear that Biomet's stock price is currently too low to entice management to announce a split. History tells us otherwise. A 3:2 split was paid on August 8th. At the time the split was announced the stock was trading at $38.00. Shares of Biomet have been in a straight up trend since mid-October. There has been a mild pullback recently in the stock, which is actually impressive, given that that the NASDAQ is getting creamed. Another explanation for the pullback is the current overbought condition, foretold by the RSI line. Although this condition has been somewhat relieved, this indicator remains near the top of its range. We have set our stop at $33.00, which is just below the support level of $33.72 offered by the 50-DMA. If the stock does make a new high this week, you can find our adjusted stop level in our In Play section. Otherwise, we will exit this play either right before the earnings or right after a split announcement.

Picked on October 31st @ $36.19 Change since picked +1.63

CEFT - Concord EFS $41.19 (-0.63)

ATM card authorization and processing service provider, Concord EFS continues to consolidate. The stock spent most of Friday's session in negative territory, trading as low as $41.06 on light volume. CEFT is having trouble clearing the 5-dma. The violation of the stock's 10-dma on declining volume gives us some reason for concern. As far as a split announcement, CEFT's last 6 splits were 3:2 splits when the stock was trading in the $30-$40 range. All 6 splits were announced following a Board of Directors meeting. Currently, the stock price is within historic split range and CEFT has enough shares for a 3:2 split. Now all we need is a BoD meeting (none currently on the horizon, but we monitor these closely). Until then, support is the 20-dma at $40.19 with additional support at the October 27th intraday low of $38.13. CEFT has resistance at the 5-dma, currently at $43, and then $44, just above the November 8th intra-day high. We are looking for additional entry points on a bounce off of $40.19 or a move above $43 on midday volume greater than 1 million shares. We are keeping our stops at $37 as protection.

Picked on Oct 31st @ $41.31 Change since picked -0.12